Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the transaction, the director now owns 2,056,931 shares of the company's stock, valued at approximately $212,645,526.78. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Noubar Afeyan also recently made the following trade(s):
- On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total value of $1,606,800.00.
- On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
- On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00.
- On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
- On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00.
Moderna Price Performance
Global crypto currency reset (41 major banks signed up)
From Stansberry Research | Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Here's everything you need to know.
Shares of Moderna stock opened at $101.41 on Friday. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.43. The business has a fifty day simple moving average of $100.63 and a 200 day simple moving average of $93.64.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion during the quarter, compared to analysts' expectations of $2.53 billion. During the same period in the previous year, the firm earned $3.61 earnings per share. The firm's quarterly revenue was down 44.9% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have issued reports on MRNA shares. Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research report on Thursday, April 11th. Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the company a "hold" rating in a research report on Friday, February 23rd. HSBC reiterated a "reduce" rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of "Hold" and an average target price of $126.49.
View Our Latest Stock Report on MRNA
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. ICA Group Wealth Management LLC acquired a new position in Moderna in the fourth quarter valued at about $27,000. First Pacific Financial bought a new stake in shares of Moderna in the third quarter valued at about $27,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the fourth quarter valued at about $27,000. Arlington Trust Co LLC lifted its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Finally, Westside Investment Management Inc. bought a new stake in shares of Moderna in the first quarter valued at about $32,000. 75.33% of the stock is owned by institutional investors and hedge funds.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
